A
Andrea Marshall
Researcher at Griffith University
Publications - 282
Citations - 8259
Andrea Marshall is an academic researcher from Griffith University. The author has contributed to research in topics: Health care & Intensive care. The author has an hindex of 39, co-authored 250 publications receiving 6348 citations. Previous affiliations of Andrea Marshall include Deakin University & University of Technology, Sydney.
Papers
More filters
Journal ArticleDOI
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Annie M. Young,Andrea Marshall,Jenny Thirlwall,Oliver Chapman,Anand Lokare,Catherine Hill,Danielle Hale,Janet A. Dunn,Gary H. Lyman,Charles Hutchinson,Peter MacCallum,Ajay K. Kakkar,FD Richard Hobbs,Stavros Petrou,Jeremy Dale,Christopher J. Poole,Anthony Maraveyas,Mark Levine +17 more
TL;DR: Rivaroxaban was associated with relatively low VTE recurrence but higher CRNMB compared with dalteparin, and safety was assessed by major bleeding and clinically relevant nonmajor bleeding (CRNMB).
Journal ArticleDOI
combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines
TL;DR: The proposed simple guidelines for combining estimates after MI may lead to a wider and more appropriate use of MI in future prognostic modelling studies.
Journal ArticleDOI
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02) : an open-label, phase 3 randomised controlled trial
Hugo Ford,Andrea Marshall,John Bridgewater,Tobias Janowitz,Fareeda Y. Coxon,Jonathan Wadsley,Wasat Mansoor,D. Fyfe,Srinivasan Madhusudan,Gary Middleton,Daniel Swinson,Stephen Falk,Ian Chau,David Cunningham,Paula Kareclas,Natalie Cook,Jane M Blazeby,Janet A. Dunn +17 more
TL;DR: The findings suggest that docetaxel can be recommended as an appropriate second-line treatment for patients with oesophagogastric adenocarcinoma that is refractory to treatment with platinum and fluoropyrimidine.
Journal ArticleDOI
aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.
Richard Gray,Daniel Rea,Kelly Handley,Sarah Bowden,P. Perry,H. M. Earl,Christopher J. Poole,T Bates,S Chetiyawardana,John Dewar,I. N. Fernando,R.J. Grieve,Jonathan Nicoll,Z Rayter,Anne Robinson,A. Salman,John Yarnold,S. Bathers,Andrea Marshall,M Lee,A C Grp +20 more
TL;DR: ATTom confirms that, in ER+ disease, continuing tamoxifen to year 10 rather than just to year 5 produces further reductions in recurrence, from year 7 onward, and breast cancer mortality after year 10.
Journal ArticleDOI
Comparison of techniques for handling missing covariate data within prognostic modelling studies: a simulation study
TL;DR: The results from this simulation study suggest that performing MICE-PMM may be the preferred MI approach provided that less than 50% of the cases have missing data and the missing data are not MNAR.